Reference

A new series of highly specific PAF-acether receptor antagonists isolated from Ginkgo biloba

A new series of highly specific PAF-acether receptor antagonists isolated from Ginkgo biloba. Braquet, P.; Spinnewyn, B.; Braquet, M.; Chabrier, E.; Taylor, J. E.; Drieu, K. (IHB Res. Lab., Le Plessis Robinson, Fr.). Adv. Pharmacol. Res. Pract., Proc. Congr. Hung. Pharmacol. Soc., 4th, Meeting Date 1985, Volume 3, 427-41. Edited by: Knoll, Jozsef, Keleman, Karoly. Pergamon: Oxford, UK. (English) 1986. CODEN: 55NPA6. DOCUMENT TYPE: Conference CA Section: 1 (Pharmacology) 3H-Labeled platelet-activating factor (PAF-acether) [65154-06-5] binding by membranes of rabbit platelets was inhibited by BN 52021 (I) [99796-69-7] (50% inhibitory concn. (IC50) 2.5 ′ 10-7M), BN52020 [15291-75-5] (IC50 9.4 ′ 10-5M, and BN52022 [15291-76-6] (IC50 1.7 ′ 10-5M). I was the most effective inhibitor of PAF-acether-induced platelet aggregation regardless of the concn. used. The antagonists were only effective against PAF-acether-induced aggregation and not against that caused by ADP, collagen, thrombin, or A 23187. In elec. stimulated rat carotid artery there was an increase in time to thrombus formation with I (20 mg/kg, orally) 30 min before the challenge. 95851-37-9 and 99796-69-7 are just another two chemicals used in this study. I and other PAF-acether antagonists constitute promising pharmacol. tools for exploring PAF-acether involvement in different models of anaphylaxis, shock, or thrombosis. .

Extracts of Ginkgo biloba for pharmaceuticals and dietary supplements

All Rights Reserved. Extracts of Ginkgo biloba for pharmaceuticals and dietary supplements. Carite, Christophe; Rull Prous, Santiago; Alaoui Ismaili, Smail; Forner, Pedro; Gaertner, Christine; Buchwald-Werner, Sybille (Cognis Ip Management G.m.b.H., Germany). PCT Int. Appl. WO 2007006443 A1 18 Jan 2007, 22pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). (World Intellectual Property Organization). CODEN: PIXXD2. APPLICATION: WO 2006-EP6429 1 Jul 2006. PRIORITY: FR 2005-52158 12 Jul 2005. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) Section cross-reference(s): 1, 17, 18 Suggested are new exts. from the leaves of G. biloba, comprising (a) 20-30% flavone glycosides, (b) 2.5-4.5% ginkgolides A, B, C and J (in total), (c) 2.0-4. 15291-77-7 and 15291-76-6 which are cas registry numbers of substances are two of reagents here. 0% . bilobalides, (d) <10 ppm alkyl phenol compds. and (e) >10% by wt. oligomeric proanthocyanidins (OPC). .